Compare BIIB & COHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | COHR |
|---|---|---|
| Founded | 1978 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 21.9B |
| IPO Year | 1991 | 1987 |
| Metric | BIIB | COHR |
|---|---|---|
| Price | $196.52 | $217.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 13 |
| Target Price | ★ $195.13 | $192.58 |
| AVG Volume (30 Days) | 1.6M | ★ 5.8M |
| Earning Date | 02-06-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.79 | 1.21 |
| Revenue | ★ $9,890,600,000.00 | $6,294,322,000.00 |
| Revenue This Year | N/A | $17.85 |
| Revenue Next Year | N/A | $15.96 |
| P/E Ratio | ★ $22.36 | $179.20 |
| Revenue Growth | 2.22 | ★ 18.63 |
| 52 Week Low | $110.04 | $45.58 |
| 52 Week High | $202.41 | $247.15 |
| Indicator | BIIB | COHR |
|---|---|---|
| Relative Strength Index (RSI) | 64.38 | 53.90 |
| Support Level | $187.20 | $209.23 |
| Resistance Level | $202.41 | $237.60 |
| Average True Range (ATR) | 6.19 | 21.00 |
| MACD | 1.76 | -0.91 |
| Stochastic Oscillator | 81.34 | 58.40 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.